Stephanie E Reuter Lange

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9042885/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Carnitine and Acylcarnitines. Clinical Pharmacokinetics, 2012, 51, 553-572.	1.6	341
2	Impact of hemodialysis on endogenous plasma and muscle carnitine levels in patients with end-stage renal disease. Kidney International, 2004, 66, 1527-1534.	2.6	59
3	Determination of the reference range of endogenous plasma carnitines in healthy adults. Annals of Clinical Biochemistry, 2008, 45, 585-592.	0.8	50
4	Reliability and validity of indices of hand-grip strength and endurance. Australian Occupational Therapy Journal, 2011, 58, 82-87.	0.6	47
5	A retrospective study to determine the cefepime-induced neurotoxicity threshold in hospitalized patients. Journal of Antimicrobial Chemotherapy, 2020, 75, 718-725.	1.3	41
6	Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 2008, 24, 990-996.	0.4	36
7	Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome. Clinical Pharmacokinetics, 2016, 55, 807-812.	1.6	36
8	Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in end-stage renal disease. Annals of Clinical Biochemistry, 2005, 42, 387-393.	0.8	35
9	Long-chain acylcarnitine deficiency in patients with chronic fatigue syndrome. Potential involvement of altered carnitine palmitoyltransferase-I activity. Journal of Internal Medicine, 2011, 270, 76-84.	2.7	33
10	Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology. British Journal of Clinical Pharmacology, 2021, 87, 227-236.	1.1	25
11	Effect of Food on the Pharmacokinetics of Piperaquine and Dihydroartemisinin. Clinical Drug Investigation, 2015, 35, 559-567.	1.1	23
12	Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. Menopause, 2015, 22, 44-49.	0.8	20
13	L-carnitine supplementation in the dialysis population: Are Australian patients missing out?. Nephrology, 2007, 13, 070712161837003-???.	0.7	19
14	Assessing the accuracy of two Bayesian forecasting programs in estimating vancomycin drug exposure. Journal of Antimicrobial Chemotherapy, 2020, 75, 3293-3302.	1.3	18
15	Optimal Practice for Vancomycin Therapeutic Drug Monitoring: Position Statement From the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2022, 44, 121-132.	1.0	18
16	Carnitine and Acylcarnitines. Clinical Pharmacokinetics, 2012, 51, 553-572.	1.6	17
17	Evaluation of a Pilot Vancomycin Precision Dosing Advisory Service on Target Exposure Attainment Using an Interrupted Time Series Analysis. Clinical Pharmacology and Therapeutics, 2021, 109, 212-221.	2.3	16
18	Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria. Journal of Antimicrobial Chemotherapy, 2015, 70, 868-876.	1.3	14

#	Article	IF	CITATIONS
19	Assessment of cefepime toxicodynamics: comprehensive examination of pharmacokinetic/pharmacodynamic targets for cefepime-induced neurotoxicity and evaluation of current dosing guidelines. International Journal of Antimicrobial Agents, 2021, 58, 106443.	1.1	13
20	Cannabinoid Disposition After Human Intraperitoneal Use: An Insight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer. Clinical Therapeutics, 2018, 40, 1442-1447.	1.1	12
21	Comparison of the Area Under the Curve for Vancomycin Estimated Using Compartmental and Noncompartmental Methods in Adult Patients With Normal Renal Function. Therapeutic Drug Monitoring, 2019, 41, 726-731.	1.0	11
22	Accuracy of documented administration times for intravenous antimicrobial drugs and impact on dosing decisions. British Journal of Clinical Pharmacology, 2021, 87, 4273-4282.	1.1	11
23	Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice. Cancer Chemotherapy and Pharmacology, 2019, 84, 1073-1087.	1.1	8
24	Population pharmacokinetics of lenalidomide in patients with Bâ€cell malignancies. British Journal of Clinical Pharmacology, 2019, 85, 924-934.	1.1	8
25	Optimising time samples for determining area under the curve of pharmacokinetic data using non-compartmental analysis. Journal of Pharmacy and Pharmacology, 2019, 71, 1635-1644.	1.2	7
26	Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis. Microbiology Spectrum, 2022, 10, .	1.2	7
27	Reducing Palivizumab Dose Requirements Through Rational Dose Regimen Design. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 26-33.	1.3	6
28	Model-Optimized Fluconazole Dose Selection for Critically III Patients Improves Early Pharmacodynamic Target Attainment without the Need for Therapeutic Drug Monitoring. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	6
29	Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer. Cancer Chemotherapy and Pharmacology, 2020, 86, 547-558.	1.1	5
30	Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1521-1528.	1.3	5
31	How â€~Optimal' are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations. Clinical Pharmacokinetics, 2016, 55, 1171-1177.	1.6	4
32	The effect of highâ€dose, shortâ€ŧerm caffeine intake on the renal clearance of calcium, sodium and creatinine in healthy adults. British Journal of Clinical Pharmacology, 2021, 87, 4461-4466.	1.1	4
33	Pharmacokinetics and Comparative Bioavailability of Artesunate and Mefloquine Administered Separately or as a Fixed Combination Product to Healthy Volunteers and Patients with Uncomplicated Plasmodium falciparum Malaria Journal of Bioequivalence & Bioavailability, 2010, 02, .	0.1	4
34	Perceived and actual paracetamol dosing inÂoverweight and obese children. European Journal of Hospital Pharmacy, 2012, 19, 438-442.	0.5	3
35	Population pharmacokinetics of ribavirin in lung transplant recipients and examination of current and alternative dosing regimens. Journal of Antimicrobial Chemotherapy, 2019, 74, 691-698.	1.3	3
36	Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. Clinical Pharmacokinetics, 2020, 59, 1013-1026.	1.6	3

#	Article	IF	CITATIONS
37	Population Pharmacokinetics of Oral-Based Administration of Cannabidiol in Healthy Adults: Implications for Drug Development. Cannabis and Cannabinoid Research, 2022, , .	1.5	2
38	Review and evaluation of vancomycin dosing guidelines for obese individuals. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 323-335.	1.5	2
39	What is the value of <scp>l</scp> â€carnitine level determination for carnitine supplementation in hemodialysis patients?. Hemodialysis International, 2013, 17, 335-338.	0.4	1